Pfizer invests EUR 54 million in Austrian-based research

© Pfizer

In its clinical research activities, Pfizer is particularly relying on the strong level of expertise in Austria.

New medicines are being developed in cooperation with local medical universities, research institutions and hospitals. Clinical research carried out by Pfizer focuses on new treatments for cancer, chronic-inflammatory diseases, cardiovascular diseases, rare diseases, pain and new vaccines. In 2017 Pfizer also invested EUR 54 million in Austria.

One example of the company’s cooperation in the field of clinical research is its partnership with the academic institution ABCSG. The study group led by Prof. Michael Gnant (Medical University of Vienna) heads a registration trial with a substance developed by Pfizer to treat breast cancer. The study is completely financed by Pfizer and ABCSG is in charge of data, patient and project management in 21 countries across the globe. 5,600 patients are to take part in the study over a period of fifteen years. 18 hospitals and about 500 patients are involved just in Austria. „The fact that responsibility for a globally implemented Phase III study is in Austrian hands is a nice acknowledgement of the longstanding work done by ABCSG”, explains Prof. Gnant, President of ABCSG.